REFEREE REPORTS:
Referee #1 (Remarks to the Author):
Godin et al present two very interesting pieces of evidence supporting a possible role for the betacatenin pathway in the toxicity caused by mutant huntingtin. First, they show that wild type and mutant huntingtin interact with the SCF(TrCP) complex responsible for ubiquitination of a number of substrates including beta-catenin. Second, they show that expression of mutant huntingtin causes stabilization of beta-catenin which coincides with a lack of interaction between beta-catenin and the SCF(TrCP) ubiquitin ligase complex. They propose that huntingtin acts as a scaffold protein that facilitates the interaction between SCF(TrCP) and beta-catenin and suggest that this scaffold function is compromised in the presence of mutant huntingtin. The researcher used cellular and animal models as well as postmortem material to study the role of beta-catenin in Huntington's disease. The data are of high quality and well presented in this clearly written manuscript. There are some overstatements and some additional experiments are required. Major concerns: 1) As I indicated above, the study is composed of two important findings namely the interaction between huntingtin and SCF(TrCP), on one hand, and the lack of interaction and stabilization of beta-catenin in the presence of mutant huntingtin, on the other hand. However, these data do not conclusively show that these two phenomena are mechanistically linked. Thus, it is not formally shown that the interaction between mutant huntingtin and SCF(TrCP) is responsible for the reduced interaction between beta-catenin and SCF(TrCP) and the stabilization of beta-catenin. It is well known that mutant huntingtin affects many processes in the cell and it cannot be excluded that the reduced interaction between beta-catenin and SCF(TrCP) reflects a functional stabilization of the protein triggered by signaling cascades activated by mutant huntingtin. Also in that case the stabilization will of course coincide with a reduced interaction between beta-catenin and the ubiquitin ligase. In vitro binding studies with recombinant proteins (SCF(TrCP) + huntingtin + betacatenin) would be required to conclusively show this. Without such experiments the authors should clearly mark this as speculation and present their model in the discussion section rather than the result section. Fig 3E should also be moved to the end of the paper and presented in the discussion to emphasize that this is a model.
2)
Extending on my previous comment, there is one important experiment that should be done in order to distinguish between stabilization of beta-catenin due to impaired binding to the SCF(TrCP) (as proposed by the authors) or functional stabilization due to an indirect effect. According to the model proposed by the authors the inhibition occurs downstream of the phosphorylation event which primes beta-catenin for ubiquitination and upstream of ubiquitination itself. This predicts that the beta-catenin should accumulate in its phosphorylated form which is unusual in the case of functional stabilization as a consequence of intracellular signaling (because in those cases phosphorylation is prevented). Thus the authors should check if the accumulated betacatenin in mutant huntingtin expressing cells is phosphorylated or not. Although the demonstration that beta-catenin is indeed phosphorylated would support their model it is not conclusive evidence which means that it should still be marked as discussion/speculation.
3)
Compelling data are presented that indomethacin prevents the mutant huntingtin-induced accumulation of beta-catenin and at the same time reduces the toxicity. However, also here there is no conclusive evidence for a causative link. Thus, although the data conclusively show that indomethacin reduces toxicity it remains to be shown that this occurs through restoration of betacatenin levels. The authors acknowledge the fact that restoration of beta-catenin may only be one of the beneficial activities but, plausible as it is, even that has not been formally shown. This claim should be toned down.
4)
The authors did not check whether the accumulation of beta-catenin results in transcriptional induction of beta-catenin targets. Experiments with the TOP/FOP reporter system, which are commonly used in the beta-catenin field, should be included to show that accumulation of beta-catenin results in transcriptional activation. Alternatively, the levels of endogenous targets could be investigated.
Minor comments 1)
Quantification should also been shown in Fig 1B (same as in 1A) .
2)
In the quantifications of western blots it should be clearly stated that the values refer to band densities (either in the figure itself or legend) to avoid that readers will think that this refer to actual levels of the proteins (western blotting is not a quantitative method).
Referee #2 (Remarks to the Author):
Godin et al. Mutant huntingtin-impaired degradation of b-catenin causes neurotoxicity in Huntington's disease Godin and colleagues describe a novel pathogenic mechanism in HD in which the polyglutamine expansion in mutant huntingtin and its small fragments can associate with the b-catenin destruction complex and interfere with degradation of b-catenin. They found that genetic and phamarcological manipulation of b-catenin levels can alter mhtt toxicity in the mammalian striatal cells and in fly models. Overall, this study provides novel and converging lines of evidence for the selective deficits of ubiquitin-proteosome-mediated degradation of b-catenin as a significant aspect of neuronal toxicity induced by mhtt and may have potential therapeutic implications. However, there are several issues the authors should address to strengthen their conclusions and to accurately reflect the relevance of their study to HD.
1.
The evidence for increased b-catenin in HD models is critical to establish the rationale for the entire study. Although the authors have used HD cellular, fly and patients tissues to shown an increase of b-catenin level by Western blots, the concern is that the changes in b-catenin levels, particularly in stage 3 and 4 HD striata, could be largely due to the change in cellular composition (e.g. the massive loss of striatal medium spiny neurons and an increase in glia). Thus, it is crucial to provide evidence (e.g. by quantitative immunostaining) in HD mice or patients that the increase of b-catenin occurs in striatal MSNs, and the level change is not simply due to loss of MSNs.
2.
Figure 2 is supposed to demonstrate that mhtt can impair the association between htt and bcatenin. However, the experiment is only performed with very high levels of mhtt fragment overexpression, raising some concerns about its physiological relevance. It would be more convincing if they could use the Hdh knock-in primary neurons and/or cell lines to show that such an association is also altered in polyQ length dependent manner.
3.
The genetic evidence in Figure 5 is particularly supportive of the role of b-catenin destruction complex protein, Slimb, in modifying mhtt fragment toxicity in the fly eye model. It is intriguing why the authors did not directly test their hypothesis that elevated armadillo (fly b-catenin homolog) is critical to eye degeneration by directly crossing the HD fly with an arm loss-of-function or RNAi fly. Moreover, there is some inconsistency in Figure 5B , in which the double transgenic fly showed almost no arm expression by Western blots but the quantitation showed comparable levels of expression as the Q0 control.
4.
Finally, the indomethacin (a NSAIDS) results are consistent with the b-catenin hypothesis, but the mechanisms and role in HD therapy are not as clear-cut as the authors suggested. NSAIDS, including indomethacin, have been suggested to suppress polyQ toxicity in cell models via increasing heat shock protein expression and suppressing aggregation (Ishihara et al, E.J.Biochem 271: 4552, 2004) . However, two such NSAIDS tested at levels that can be tolerated in mammals did not show beneficial effects in two HD fragment models (Norflus et al, Neurobio. Disease 17: 319, 2004) . Such relevant literature on NSAIDS and HD should be included and discussed. Due to the pleiotropic effects of NSAIDS, in addition to the modulation of b-catenin levels, the relatively modest effects of indomethacin on fly HD survival (prolonged by only 1.6 days) and lack of a preclinical study with indomethacin in mammalian model of HD, the authors should take extra caution in presenting such data. The current manuscript stating "we thus suggest that indomethacin could be used to treat HD" is a clear overinterpretation of the available evidence.
Minor issues 1. In Figure 4 , it would be important to include some control data. First, in 4b, it would be helpful to include a control of wildtype f-box, and/or f-box engineered to have a substrate other than b-catenin. Second, in Fig. 4C , it would be important to show that the si-b-catenin siRNA can selectively reduce b-catenin mRNA in cells.
Referee #3 (Remarks to the Author):
In this manuscript, the authors observed accumulation of beta-catenin by mutant huntingtin (Htt) containing expanded polyQ stretch in cultured neurons, HD drosophila model and HD patients. They also showed that Htt interacts with both beta-catenin and its destruction complex components including beta-TrCP and axin, and mutant Htt disrupts the interaction of beta-catenin with the destruction components, resulting in stabilization of beta-catenin. Finally, they tried to inhibit betacatenin accumulation by several methods including knockdown of beta-catenin, overexpression of beta-TrCP, and treatment with an NSAID, indomethacin, and showed that reduction of beta-catenin suppresses mutant Htt-induced toxicity in HD cellular model and its drosophila model. From these data, the authors conclude that mutant Htt impairs beta-catenin degradation in a specific mechanism to induce neurotoxicity and its inhibition is neuroprotective in HD.
Their findings are interesting and important for understanding of HD pathological mechanism, which could be a potential target for HD therapy. However, a number of points listed below should be clarified.
Major points; 1) Is the accumulation of beta-catenin also observed in knock-in mouse and/or HD mouse models? This could be shown using knock-in mouse brain.
2) Is beta-catenin associated specific to huntingtin or can be associated with other expanded polyglutamine proteins such as ataxin 3?
3) In Figure 2A , the authors have examined the interaction of exogenous beta-TrCP with endogenous htt, but significant amounts of htt appear to be precipitated with IgG control. Is the interaction between these two proteins specific? A control data using IgG and HdhQ111/Q111 knock-in mice are missing. figure 2B , the authors showed co-immunoprecipitation of beta-TrCP by anti-Htt antibody from wild type or mutant Htt knock-in mice brains. This should be confirmed by reverse experiment using antibody against beta-TrCP for immunoprecipitaiton. figure 3A , the authors should perform immunoprecipitation experiment control experiments using control IgG. to confirm the interaction between beta-catenin and Htt. Reverse experiment using beta-catenin antibody is also required. figure 3A , the reason why they used longer htt (1301 aa) for this experiment is unclear. Is htt containing 480 aa not sufficient for interaction with beta-catenin? Also, the region/domain of htt for interaction with beta-TrCP and axin was not unclear, which should be clarified. figure 3E , the authors provide a model in which htt seems to directly bind to all of the proteins including beta-TrCP, axin and beta-catenin based on their immunoprecipitation data. However, it is also possible htt indirectly binds to one of them through other proteins. To exclude this, the authors should examine the direct interactions of htt with the proteins shown here using in vitro system. 8) In figure 4 , there are no data of the reduction of beta-catenin, which should be shown.
4) In

5) In
6) In
7) In
9) The data of neurotoxicity by overexpression of beta-catenin in cellular and/or Drosophila models may reinforce the authors' conclusion. We do agree that in vitro binding studies are required to unequivocally state that the interaction between mutant huntingtin and SCF(TrCP) is responsible for the reduced interaction between betacatenin and SCF(TrCP) and the stabilization of beta-catenin. This is clearly something we would have aimed to perform as it is of course of great scientific interest. In particular, we did notice that it is possible to assemble a beta-Trcp/ beta-catenin complex in vitro (see for example: Hart M. et al., Current Biol., 1998; Winston J.T. et al., Genes and Dev 1999) . However the limitation is the obtention of recombinant huntingtin protein. Since the last 10 years, we (including F. Saudou's laboratory) and others tried several times to obtain purified huntingtin for other in vitro experiments and did not succeed. Huntingtin is a 350 kDa protein that does not express in bacteria due to its large size. When containing the polyQ stretch, huntingtin aggregates once produced in vitro. We tried baculovirus approaches but obtained very small amounts that also aggregate and that are not appropriate/sufficient for in vitro experiments. In our study, we would need to work with a fragment of 480 amino acids and with the current available tools, it is very difficult to obtain such soluble purified fragments. It would be even more difficult to obtain the mutated form to compare the httbeta-catenine-beta-trcp complex in the WT and disease situations (which is the goal of the proposed experiment). Please also note that the litterature does not provide one example of successful production and purification of such fragments of huntingtin. Further, the crystal structure of huntingtin (even fragments) is unknown and this is certainly linked to this difficulty of producing recombinant huntingtin protein. Finally, we do see an accumulation of phosphorylated beta-catenin (see point 2). Altough this remains correlative, it strongly supports our model despite the absence of in vitro assembly of complexes. Therefore, we describe Figure 3E in the discussion as a speculative model (new Figure 6F) .
2)
Extending We have determined the phosphorylation status of beta-catenin by analyzing by immunoblotting the levels of phosphorylated beta-catenin at positions 33-37-41 and 41-45. We found that beta-catenin accumulates in its phosphorylated form in an HD knock-in mouse line (CAG140) and in postmortem samples from HD brains. As pointed out by the reviewer, while not conclusive, this further supports our model as now discussed in the new version of the manuscript (new Figures 1E-H We agree with the reviewer and have modified our statements accordingly (see for instance pages 2, 13, 18; see also point 4 of referee #2).
4)
The As suggested by the reviewer, we have analyzed the levels of c-myc and axin2 by RT Q-PCR in CAG140 knock-in HD mice as compared to their wild-type littermates. c-myc and axin2 are two well-described endogenous targets of beta-catenin. We found no difference in the levels of these transcripts. We conclude that accumulation of beta-catenin in HD pathological situation does not result in a global transcriptional activation (new Figure 1I and J, results page 7). This is in agreement with our observations showing that beta-catenin accumulation occurs under its phosphorylated form (discussion page 18).
Minor comments
1)
We have included the requested quantification that reveals an increase of beta-catenin in cells expressing polyQ-huntingtin with a value close to statistical significance (three independent experiments). In the three experiments, we observed an increase in beta-catenin levels but the statistical significance was not reached due to the variability in the amplitude of this increase between experiments. However, as requested by referee 3, in the new version of the manuscript, we rather assessed the levels of beta-catenin in brains from two different knock-in mouse models. In these models, which are more relevant to the study, the increase in beta-catenin levels is statistically significant ( Figure 1D and E and supplementary Figure S1A ).
2) In the quantifications of western blots it should be clearly stated that the values refer to band densities (either in the figure itself or legend) to avoid that readers will think that this refer to actual levels of the proteins (western blotting is not a quantitative method).
We clearly stated that the values refer to band densities (legends of Figures 1, 3, 4 and 5). We agree with the reviewer and have performed two set of experiments.
Referee #2:
Godin et al. Mutant huntingtin-impaired degradation of b-catenin causes neurotoxicity in Huntington's disease. Godin and colleagues describe a novel pathogenic mechanism in HD in which the polyglutamine expansion in mutant huntingtin and its small fragments can associate with the bcatenin destruction complex and interfere with degradation of b-catenin. They found that genetic and phamarcological manipulation of b-catenin levels can alter mhtt toxicity in the mammalian striatal cells and in fly models. Overall, this study provides novel and converging lines of evidence for the selective deficits of ubiquitin-proteosome-mediated degradation of b-catenin as a significant aspect of neuronal toxicity induced by mhtt and may
First, we performed immunohistochemical staining of brain sections from 12 month old CAG140 mice. We found beta-catenin almost exclusively in the neuropil in the striatum. Beta-catenin staining was surrounding NeuN staining. In the thalamus, beta-catenin was nuclear. This localization is in agreement with a previous work by Lucas, J.J. et al. (NeuroReport, 1999) . An example is shown in supplementary Figure S1B . We compared 3 wild-type to 3 knock-in mice and found that betacatenin levels tend to be increased in striatal neuropil of the CAG140 knock-in mice compared to their wild-type littermates. However, due to the small number of samples and the neuropilic diffuse localization of beta-catenin, the results are difficult to quantify accurately and we thus prefer not to include the comparison of beta-catenin striatal staining between wild-type and CAG mice. Please also note that gliosis is not increased in striatum until two years of age in CAG140 knock-in mice (Hickey et al., Neuroscience, 2008) .
Second, cortical extracts from 8 month old CAG140Q mice did not show profound modification of bIII-tubulin and glial fibrillary acidic protein GFAP, respectively neuronal and glial markers, while beta-catenin accumulated in the same extracts (New Figure 1D) . Similar observations were made in striata of CAG140 mice and Hdh Q111/Q111 mice (data not shown).
In conclusion, we have shown that beta-catenin levels are increased in HD and that this increase is not simply the consequence of neuronal loss and gliosis. The text was modified (page 6).
Figure 2 is supposed to demonstrate that mhtt can impair the association between htt and b-catenin. However, the experiment is only performed with very high levels of mhtt fragment overexpression, raising some concerns about its physiological relevance. It would be more convincing if they could use the Hdh knock-in primary neurons and/or cell lines to show that such an association is also altered in polyQ length dependent manner.
We believe that the reviewer refers to former Figure 3 . In agreement with the reviewer's comment, it is indeed closer to the physiological situation to assess the interactions of endogenous proteins. In Figure 3B , using a huntingtin immunoprecipitation experiment from mouse brain extracts, we now show that endogenous huntingtin interacts with endogenous beta-catenin. This association is decreased when endogenous huntingtin contains an abnormal polyQ expansion (cortical extracts from Hdh Q111/Q111 knock-in mice). We also performed the converse immunoprecipitation experiment using a anti-beta-catenin antibody ( Figure 3C ) and consistently observed that beta-catenin binds huntingtin in a polyQ-dependent manner. The text was modified accordingly (pages 8 and 9).
The genetic evidence in Figure 5 is particularly supportive of the role of b-catenin destruction complex protein, Slimb, in modifying mhtt fragment toxicity in the fly eye model. It is intriguing why the authors did not directly test their hypothesis that elevated armadillo (fly bcatenin homolog) is critical to eye degeneration by directly crossing the HD fly with an arm loss-offunction or RNAi fly.
We did not perform this experiment and rather tested the effect of expressing Slimb, as armadillo loss-of-function was already tested in the study from Kaltenbach et al. (PLoS Genet, 2007) . The authors reported that loss-of-functions alleles suppresses polyQ-huntingtin-induced toxicity. This is included in the discussion (page 14). Figure 5B , in which the double transgenic fly showed almost no arm expression by Western blots but the quantitation showed comparable levels of expression as the Q0 control.
Moreover, there is some inconsistency in
We now show a more representative immunoblot (new Figure 5B) .
4.
Reviewer 1 raised a similar concern. We agree that some of our statements should be toned down and have modified the text accordingly (see for instance pages 2, 13, 18). In particular, we thank reviewer 2 for the useful informations and references. We have included and discussed the relevant litterature (page 17).
In conclusion, we strongly feel we have shown that restoring beta-catenin homeostasis is protective in cellular and Drosophila models of HD (see Figures 4 and 5) . The effect of indomethacin could indeed be due to its other targets including heat shock proteins (Ishihara, K. et al., Eur J Biochem, 2004) . Finally, the fact that anti-inflammatory compounds, such as celecoxib, acetylsalicylate and rofecoxib, did not show beneficial effects in transgenic HD mice expressing short fragments of polyQ-huntingtin to model HD could be linked to the mouse models used (Norflus, F. et al., Neurobiol Dis, 2004; Schilling, G. et al., Exp Neurol, 2004) . In these models, short fragments (either exon 1 corresponding to three percent of total huntingtin or a 171 amino acid fragment) of polyQhuntingtin are used giving rise to a severe pathology with a fast progression. The fragments used may not be sufficient to interact with beta-catenin and/or beta-TrCP and therefore such models may not be relevant to study molecules counteracting the toxic effect of this pathway. Further studies in full-length mouse models of HD are necessary.
Minor issues
1. In Figure 4 , it would be important to include some control data. First, in 4b, it would be helpful to include a control of wild-type f-box, and/or f-box engineered to have a substrate other than bcatenin.
We apologize for the lack of clarity: F-boxTcf4 and F-boxEcad ( Figure 4B ) correspond to betaTrCP in which the wild-type WD40-repeat of beta-TrCP was replaced with the beta-catenin binding domain from Tcf4 or E-cadherin respectively. The corresponding control is therefore beta-TrCP with its wild-type binding domain (as used in Figure 4A ). While misleading, we used the nomeclature F-boxTcf4 and F-boxEcad as it is the published one (Liu, J. et al., BBRC, 2004) . We clarified the text (page 10).
To our knowledge, an F-box engineered to have a substrate other than beta-catenin does not exist. What does exist are chimeric molecules that artificially target proteins to the SCF complex for ubiquitination and degradation (see for instance: Sakamoto, K.M. et al., PNAS, 2001 ). However, their use would not be appropriate in our study. Fig. 4C , it would be important to show that the si-b-catenin siRNA can selectively reduce b-catenin mRNA in cells.
Second, in
We included the requested control immunoblotting showing that the siRNA targeting beta-catenin efficiently reduces beta-catenin level (new Figure 4C ). In new Figures 1D, 1E and 1F, we now show that beta-catenin accumulates in the brain of 8 and 22 month old CAG140 knock-in mice. Similar observations can be made in Hdh Q111/Q111 knock-in mice (Supplementary Figure S1A) . In these extracts, we also have determined the phosphorylation status of beta-catenin and found that beta-catenin accumulates in its phosphorylated form. The results section was modified accordingly (pages 5-6).
2) Is beta-catenin associated specific to huntingtin or can be associated with other expanded polyglutamine proteins such as ataxin 3?
We analyzed whether beta-catenin associates with two other polyQ proteins, SCA3 and SCA7. SCA3 is particularly relevant as it binds ubiquitin and is involved in proteasomal protein degradation (Chai, Y. et al., J Biol Chem, 2004 ). We did not find an interaction betwen beta-catenin and SCA3 or SCA7. This experiment suggests that huntingtin and not other polyQ-containing proteins specifically interacts with beta-catenin. This results are shown in Supplementary Figure  S2A and B (text pages 8 and 16). Figure 2A , the authors have examined the interaction of exogenous beta-TrCP with endogenous htt, but significant amounts of htt appear to be precipitated with IgG control. Is the interaction between these two proteins specific? A control data using IgG and HdhQ111/Q111 knock-in mice are missing.
3) In
We should first acknowledge the fact that it is very difficult to work with beta-TrCP. The commercially available anti-mouse beta-TrCP antibody is not a great antibody. It does not work well for immunoblotting experiments and does not immunoprecipitate endogenous beta-TrCP in our assays. However, we repetitively observed an interaction of huntingtin with beta-TrCP which we found extremely specific.
We do not have a control data using IgG and Hdh Q111/Q111 knock-in mice as we did not have enough material to perform this control experiment (we are starting from cortical culture from E15 mouse embryos). During the time of the review process, we were unsuccessfull in getting more material given the actual size of our mouse colony. figure 2B , the authors showed co-immunoprecipitation of beta-TrCP by anti-Htt antibody from wild type or mutant Htt knock-in mice brains. This should be confirmed by reverse experiment using antibody against beta-TrCP for immunoprecipitaiton.
4) In
As for point 3, we agree with the reviewer. Indeed, when possible it is better to perform the converse experiment. However, the commercially available anti-mouse beta-TrCP antibody did not work for immunoprecipitation experiments. Please see also our answer to point #3. figure 3A , the authors should perform immunoprecipitation experiment control experiments using control IgG. to confirm the interaction between beta-catenin and Htt. Reverse experiment using beta-catenin antibody is also required. Figure 3A is an huntingtin immunoprecipitation from cells transfected with an empty plasmid (lane 1). Instead of repeating the converse experiment from transfected cells, we assessed the interaction of endogenous huntingtin and beta-catenin. In Figure  3B , using an huntingtin immunoprecipitation from mouse brain extracts, we show that huntingtin interacts with beta-catenin. This association is decreased when endogenous huntingtin contains an abnormal polyQ expansion (cortical extracts from Hdh Q111/Q111 knock-in mice). We performed the converse immunoprecipitation experiment using an anti-beta-catenin antibody ( Figure 3C ) and consistently observed that beta-catenin binds huntingtin in a polyQ-dependent manner. The text was modified accordingly (pages 8 and 9). figure 3A , the reason why they used longer htt (1301 aa) for this experiment is unclear. Is htt containing 480 aa not sufficient for interaction with beta-catenin? Also, the region/domain of htt for interaction with beta-TrCP and axin was not unclear, which should be clarified.
5) In
The control immunoprecipitation for
6) In
We initially used 1301 amino acid fragments as these fragments immunoprecipitate efficiently from cells extracts. However, we now show that the 480 amino acid fragment of huntingtin (Supplementary Figure S2A) is sufficient for interaction with beta-catenin. In summary, full-length endogenous huntingtin interacts with beta-catenin ( Figures 3B and 3C ) and the first 480 N-terminal amino acids are sufficient for interaction with beta-catenin. Similarly, full-length huntingtin interacts with beta-TrCP and the 480 amino acid fragment is also sufficient for interaction with beta-TrCP (Figure 2 ). This is clarified in the new version of the manuscript (text page 8). figure 3E , the authors provide a model in which htt seems to directly bind to all of the proteins including beta-TrCP, axin and beta-catenin based on their immunoprecipitation data. However, it is also possible htt indirectly binds to one of them through other proteins. To exclude this, the authors should examine the direct interactions of htt with the proteins shown here using in vitro system. Reviewer 1 raised a similar concern (point1):
7) In
We do agree that in vitro binding studies are required to unequivocally state that the interaction between mutant huntingtin and SCF(TrCP) is responsible for the reduced interaction between betacatenin and SCF(TrCP) and the stabilization of beta-catenin. This is clearly something we would have aimed to perform as it is of course of great scientific interest. In particular, we did notice that it is possible to assemble a beta-Trcp/ beta-catenin complex in vitro (see for example : Hart M. et al., Current Biol., 1998; Winston J.T. et al., Genes and Dev 1999) . However the limitation is the obtention of recombinant huntingtin protein. Since the last 10 years, we (including F. Saudou's laboratory) and others tried several times to obtain purified huntingtin for other in vitro experiments and did not succeed. Huntingtin is a 350 kDa protein that does not express in bacteria due to its large size. When containing the polyQ stretch, huntingtin aggregate once produced in vitro. We tried baculovirus approaches but obtained very small amounts that also aggregate and that are not appropriate/sufficient for in vitro experiments. In our study, we would need to work with a fragment of 480 amino acids and with the current available tools, it is very difficult to obtain such soluble purified fragments. It would be even more difficult to obtain the mutated form to compare the httbeta-catenine-beta-trcp complex in the WT and disease situations (which is the goal of the proposed experiment). Please also note that the litterature does not provide one example of successful production and purification of such fragments of huntingtin. Further, the crystal structure of huntingtin (even fragments) is unknown and this is certainly linked to this difficulty of producing recombinant huntingtin protein.
